[
Abstract]
[
Full Text HTML]
[
Full Text PDF] （in Japanese / 11495KB）
[PDF: Members Only] J.Jpn. Surg. Soc.. 123(1): 47-52, 2022
Feature topic
REGENERATIVE MEDICINE FOR SEVERE HEART FAILURE
Heart failure is a life-threatening disorder worldwide, and the current end-stage treatments for severe heart failure are replacement therapies such as ventricular-assist devices and heart transplantation. Although these therapies have been useful, there are many issues in terms of durability, complications, limited donors, adverse effects of continuous administration of immunosuppressive agents, and high costs involved. Recently, regenerative therapy based on genetic, cellular, or tissue engineering techniques has gained attention as a new approach to overcome the challenges encountered in transplantation medicine. To supply cardiomyocytes to the distressed myocardium, we have developed a human induced pluripotent stem (iPS) cell-derived cardiomyocyte sheet and obtained proof of concept with evidence of synchronous movement with the recipient myocardium. We have also established large culture system to determine the safety of GMP-grade iPS cell-derived cardiomyocyte sheets for clinical trials by the development of a new method for the removal of immature iPS cells.
To read the PDF file you will need Adobe Reader installed on your computer.